<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04566796</url>
  </required_header>
  <id_info>
    <org_study_id>234</org_study_id>
    <nct_id>NCT04566796</nct_id>
  </id_info>
  <brief_title>Effectiveness of Sugammadex on Muscle Relaxant Reversal in Preterm Neonates</brief_title>
  <official_title>Effectiveness of Sugammadex on Muscle Relaxant Reversal in Preterm Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the work is to compare the efficacy of Sugammadex and neostigmine in&#xD;
      reversing rocuronium-induced muscle relaxation to reach complete recovery of neuromuscular&#xD;
      block (TOF ratioâ‰¥ 0.9) in preterm neonates.&#xD;
&#xD;
      The secondary aim is to evaluate the safety of using Sugammadex in preterm neonates and to&#xD;
      detect any complications that may occur in this age group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>via the closed envelope method</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of reversal</measure>
    <time_frame>immediately after the surgery</time_frame>
    <description>Reversal time which is defined as time in seconds from the start of administration of sugammadex or neostigmine to recovery of TOF ratio to 0.9</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of recovery</measure>
    <time_frame>immediately after the surgery</time_frame>
    <description>Time for modified Aldrete score to reach 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients with Complications</measure>
    <time_frame>immediately after the surgery</time_frame>
    <description>any complication during recovery will be noted</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sugammadex</condition>
  <arm_group>
    <arm_group_label>(Group N)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in this group will receive 0.02 mg/kg atropine with neostigmine 0.05 mg/kg IV. to reverse the action of the neuromuscular blocker given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Group S)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the patients will receive Sugammadex 2mg/kg IV. As the reversal agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>give 2 mg/ kg as muscle reversal drug in premature infants</description>
    <arm_group_label>(Group S)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>give 0.02 mg/ kg atropine and 0.05 mg/kg neostigmine IV. as muscle reversal drug in premature infants</description>
    <arm_group_label>(Group N)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  preterm neonates&#xD;
&#xD;
          -  scheduled for elective inguinal hernia repair&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  drug hypersensitivity&#xD;
&#xD;
          -  patient is with any diseases affecting the neuromuscular junction&#xD;
&#xD;
          -  Patients with family history of malignant hyperthermia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M Elshafie</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yasser M osman</last_name>
    <phone>+201006357996</phone>
    <email>yasseralx@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alexandria university</name>
      <address>
        <city>Alexandria</city>
        <zip>0203</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed M osman</last_name>
      <phone>01006357996</phone>
      <email>yasseralx@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Yasser m osman, assistant professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ahmed M elshafie, lecturer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Yasser Mohamed Mohamed Osman</investigator_full_name>
    <investigator_title>assistant professor of anesthesia Alexandria university</investigator_title>
  </responsible_party>
  <keyword>Sugammadex</keyword>
  <keyword>preterm neonates</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Hypotonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

